Skip to main content
Signal8

UPDATED: NorthStrive Biosciences Files New U.S. Patent Application Covering EL-22 Formulations and Dosing for Treatment of Muscle-Wasting Conditions related to GLP-1 Use, Sarcopenia, Muscle Disuse Atrophy, and Certain Neurological Disorders

$ELABPress releaseApr 28, 2026, 4:01 PM ETRead the release

NorthStrive Biosciences, a wholly owned subsidiary of PMGC Holdings Inc. (ELAB), filed a U.S. patent application covering formulations and dosing regimens for its EL-22 myostatin-engineered probiotic. The application seeks intellectual property protection for the treatment of muscle-wasting conditions, including loss associated with GLP-1 receptor agonist therapy, sarcopenia, and neurological disorders.

Key figures

Patent Application Number
19/655,160

AI analysis

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.

    ELAB: UPDATED: NorthStrive Biosciences Files New U.S. Patent Application Covering EL-22 Formulations and Dosing for Treatment of Muscle-Wasting Conditions related to GLP-1 Use, Sarcopenia, Muscle Disuse Atrophy, and Certain Neurological Disorders — AI Analysis | Signal8